Nocturnal enuresis (NE), commonly known as bed-wetting, affects a significant number of school-age children. Beyond the immediate inconvenience, persistent NE can have profound effects on a child's self-esteem, sleep quality, family dynamics, and social functioning. Recognizing this, an updated expert consensus has been published, offering a practical framework for clinicians to diagnose, classify, and treat childhood NE. The consensus, which includes 18 recommendations, aims to shift practice from a symptom-based approach to one that is standardized, individualized, and family-centered.
The new framework, published in the World Journal of Pediatrics, lowers the diagnostic threshold for NE. Children aged five years and older who experience at least one involuntary nighttime void per month for three months now meet the diagnostic criteria, a change from the previous weekly standard. This modification enables earlier intervention, which is crucial for mitigating the negative impacts of the condition.
A key aspect of the consensus is the distinction between monosymptomatic NE (MNE), where no daytime lower urinary tract symptoms (LUTS) are present, and non-monosymptomatic NE (NMNE), which includes daytime symptoms such as urgency, frequency, or incontinence. This classification drives all subsequent treatment decisions. The use of a voiding diary is emphasized as a diagnostic cornerstone, with patients required to record at least two daytime charts and seven consecutive nights of fluid intake and voids. This allows clinicians to phenotype children as having nocturnal polyuria, reduced bladder capacity, or both.
For MNE, treatment is phenotype-driven: desmopressin is recommended for nocturnal polyuria, while the enuresis alarm is preferred for reduced bladder capacity. Combination therapy is suggested for mixed types. In contrast, NMNE management prioritizes addressing daytime LUTS and comorbidities, particularly constipation, which affects 36–80% of these children, before targeting nighttime wetting. The consensus also outlines clear referral criteria: primary care can manage MNE, but non-responders or suspected NMNE require specialist evaluation, which may include urodynamics and lumbosacral magnetic resonance imaging (MRI). Refractory cases, defined as less than 50% improvement after three months, should undergo systematic re-evaluation of adherence, diary findings, and underlying causes before treatment escalation.
The authors, from the Department of Nephrology at the Children's Hospital of Fudan University and the Chinese Cooperative Group for the Management of Pediatric NE, stress that NE should not be treated as a uniform disorder. The updated pathway asks clinicians to identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while involving the family. They emphasize that apparent treatment failure should prompt a careful review of adherence, voiding records, and possible missed conditions before adding stronger therapy.
In practice, these recommendations could help pediatricians and primary-care clinicians identify which children can be managed locally and which need specialist assessment. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment. Earlier attention to constipation, sleep-disordered breathing, attention-deficit/hyperactivity disorder (ADHD), and daytime urinary symptoms could improve response rates. The framework also encourages timely referral when first-line therapy fails or NMNE is suspected, supporting better coordination across levels of care.
While the consensus reflects Chinese practice patterns and acknowledges limited evidence in areas such as desmopressin withdrawal strategies, it provides a valuable roadmap for improving care for children with NE. Future trials and multidisciplinary care models could further refine individualized treatment approaches.
